Treatment News : Transplant Drugs May Fight HIV Reservoir

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

April 14, 2014

Transplant Drugs May Fight HIV Reservoir

Immunosuppressant drugs used to prevent rejction of transplanted organs may combat the HIV reservoir. Publishing their findings in the American Journal of Transplantation, researchers studied how the transplant drug sirolimus (rapamycin) affected the disease state of 91 HIV-positive transplantees, whom they followed for a median 3.2 years.

The researchers examined blood samples taken from the study participants—most of whom were on antiretroviral therapy—a respective 12, 26, 52 and 104 weeks following their transplants.  

The investigators found that those who took sirolimus had lower levels of HIV DNA. They theorized that the drug may reverse the latency of cells harboring HIV, causing the cells to produce HIV and possibly leading to an ultimate drop in the HIV DNA levels.  (Antiretrovirals cannot attack HIV that is in a latent cell.  But once the cell is activated ARVs can protect uninfected cells from the virus that the awakened cell produces, and researchers hope the virus will ultimately kill that cell.)

“Our study highlights the potential synergies that can occur when two very different disciplines merge their talents and resources,” lead author Steven Deeks, MD, of the University of California, San Francisco, said in a release.

Deeks theorizes that sirolimus may have other HIV-fighting benefits: including making immune cells less susceptible to infection by reducing the expression of the CCR5 coreceptors onto which the virus attaches before infecting the cells; and by increasing other immune responses that target the virus.

To read the abstract, click here.

To read the press release, click here.

Search: HIV, transplant, anti-rejection drugs, immunosuppressants, sirolimus, rapamycin, American Journal of Transplantation, reservoir, Steven Deeks.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.